



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/063,718	05/08/2002	Dan L. Eaton	P3230R1C001-168	8618

30313 7590 07/29/2004

KNOBBE, MARTENS, OLSON & BEAR, LLP  
2040 MAIN STREET  
FOURTEENTH FLOOR  
IRVINE, CA 92614

EXAMINER

WEGERT, SANDRA L

ART UNIT	PAPER NUMBER
----------	--------------

1647

DATE MAILED: 07/29/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>Office Action Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	10/063,718	EATON ET AL.	
	<b>Examiner</b>	<b>Art Unit</b>	
	Sandra Wegert	1647	

**-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --**  
**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

- 1) ☒ Responsive to communication(s) filed on 17 September 2002.
- 2a) ☐ This action is **FINAL**.                      2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

- 4) ☒ Claim(s) 1-20 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1-20 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☒ Claim(s) 1-20 are subject to restriction and/or election requirement.

#### Application Papers

- 9) ☒ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 08 May 2002 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  
a) ☐ All    b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- \* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

- |  |   |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)  | 4) <input type="checkbox"/> Interview Summary (PTO-413)<br>Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)   | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)             |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)<br>Paper No(s)/Mail Date <u>9/17/02</u> . | 6) <input type="checkbox"/> Other: _____  |

### **Detailed Action**

#### ***Status of Application, Amendments, and/or Claims***

The Preliminary Amendment, submitted 10 September 2002, and the Information Disclosure Statement, submitted 17 September 2002, have been entered.

Claims 1-20 are under examination in the Instant Application.

#### **Informalities**

##### ***Specification***

The disclosure is objected to because of the following informalities:

##### ***URL's***

The disclosure is objected to because it contains browser-executable code. This occurs, for example, in paragraph 206. All URL's should be removed from the Specification. Applicant may refer to web sites by non-executable name only. See MPEP § 608.01 (p).

Appropriate correction is required.

##### ***Continuity***

This application claims priority to the following patent applications: US provisional application 60/100,683, PCT/US99/20111, US application 09/403,297, PCT/US00/23328 and US application 10/006,867. Applicant has not complied with one or more conditions for receiving the benefit of an earlier filing date under 35 U.S.C. 119(e) as follows: Provisional and parent patent applications 60/100,930, PCT/US99/20111, US application 09/403,297 do not list

Art Unit: 1647

or refer to: SEQ ID NO: 93 or Figure 93. Furthermore, parent applications do not describe or disclose data that would impart Utility to the instant invention; as well, the instant Invention lacks Utility. Therefore, for this Office Action, the filing date of 3 May 2002 is considered as the priority date.

### **Claim Rejections/Objections**

#### ***Claim Rejections - 35 USC § 101 and 35 USC § 112, first paragraph***

The following is a quotation of 35 U.S.C. 101:

**Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.**

The following is a quotation of the first paragraph of 35 U.S.C. 112:

**The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.**

Claims 1-20 are rejected under 35 U.S.C. 101 because the claimed invention lacks a credible, specific and substantial asserted utility or a well-established utility.

The claims are directed to nucleotides which encode a polypeptide of 257 amino acids (see Figure 93 and SEQ ID NO: 93). Further claim limitations are presented to isolated nucleic acids having at least 80% sequence identity to a nucleic acid encoding the polypeptide of SEQ ID NO: 94 or encoding the polypeptide lacking its associated signal peptide. Claims are also presented encompassing vectors and cells comprising nucleic acids having at least 80% sequence

Art Unit: 1647

identity to SEQ ID NO: 93. However, the specification does not disclose a function for the nucleotide of SEQ ID NO: 93, encoding the polypeptide of SEQ ID NO: 94, in the context of the cell or organism.

No well-established utility exists for newly isolated complex biological molecules. However, the specification asserts the following as credible, specific and substantial patentable utilities for the claimed putative polynucleotide and polypeptide encoded by the claimed polynucleotide:

- 1) To make hybridization probes to detect the polynucleotide of SEQ ID NO: 93.
- 2) To produce the PRO1328 polypeptide and fragments.
- 3) For use in chromosome mapping.
- 4) For use in the construction of “knock-in” or “knock-out” organisms.
- 5) For making antisense oligonucleotides.
- 6) In assays to screen for compounds capable of modifying the interaction between receptor and ligand.
- 7) To make antibodies to the polypeptide encoded by the polynucleotide of SEQ ID NO: 93.
- 8) In tissue typing.
- 9) To detect and treat cancer (paragraph 531).

Each of these shall be addressed in turn:

- 1) To make hybridization probes to detect the polynucleotide of SEQ ID NO: 93.*

This asserted utility is not specific or substantial. Hybridization probes and primers can be designed from any polynucleotide sequence. The specification does not disclose specific cDNA, DNA, or RNA targets. Further, since this asserted utility is not present in mature form, so that it could be readily used in a real world sense, the asserted utility is not substantial.

2) *To produce the PRO1328 polypeptide and fragments.* This asserted utility is also substantial, but not specific. Many nucleotide sequences can be used to make polypeptides. However, if the specification discloses nothing specific and substantial about the polynucleotides or polypeptides, both the polynucleotides and polypeptides produced have no patentable utility.

3) *For use in chromosome mapping.* This asserted utility is neither substantial nor specific. Probes and primers can be designed from any polynucleotide sequence and used for chromosomal localization of a gene of interest; thus the asserted utility is not specific. Further, the specification does not disclose specific cDNA, DNA, or RNA targets. Since this asserted utility is not present in mature form, so that it could be readily used in a real world sense, the asserted utility is not substantial.

4) *For use in the construction of "knock-in" or "knock-out" organisms.* This asserted utility is not specific or substantial. The specification does not disclose diseases associated with a mutated, deleted, or translocated PRO1328 gene. Significant further experimentation would be required of the skilled artisan to identify any such a disease. The specification discloses nothing about the phenotypic result when the PRO1328 gene is "knocked in" or "knocked out" or what specific tissues and cells are being targeted. Since this asserted utility is not present in mature form, so that it could be readily used in a real world sense, the asserted utility is not substantial.

5) *For making antisense oligonucleotides.* This asserted utility is not specific or substantial. Such can be performed for any polynucleotide. Further, the specification does not disclose diseases or conditions associated with the PRO1328 gene. Significant further experimentation would be required of the skilled artisan to identify individuals in need of antisense treatment, to determine the route of administration of the antisense, as well as to determine gene targets and quantity and duration of treatment. Since this asserted utility is also not presented in mature form, so that it could be readily used in a real world sense, the asserted utility is not substantial.

6) *In assays to screen for compounds capable of modifying the interaction between receptor and ligand.* This asserted utility is substantial but not specific. Such can be performed for any receptor-ligand pair. Additionally, the specification discloses nothing specific or substantial for the compounds that can be identified by this method.

7) *To make antibodies to the polypeptide encoded by the polynucleotide of SEQ ID NO: 93.* This asserted utility is substantial, but not specific. Antibodies can be made to any polypeptide. However, if the specification discloses nothing specific and substantial about the polypeptide, the polypeptide, the polynucleotide encoding the polypeptide and antibodies have no patentable utility.

8) *In tissue typing.* This asserted utility is not substantial or specific. Such assays can be performed with any polypeptide encoded by a polynucleotide; thus, the asserted utility is not specific. Furthermore, the specification discloses limited tests of tissue expression. Applicant implies that this expression pattern supports a useful function of the polynucleotide encoding the PRO1328 polypeptide. However, patentable utility of tissue typing for the claimed

Art Unit: 1647

polynucleotide encoding the PRO1328 polypeptide is not substantial, because one skilled in the art would not readily use the nucleotide sequences for tissue-typing in a real world sense as the protein is not specific to one tissue and is not associated with any disease or disorder. This asserted utility is also not specific because numerous unrelated nucleotide sequences would also show a similar tissue typing pattern. In addition, evidence of mere expression in a tissue is not tantamount to a showing of a role for the polynucleotide of the present invention. It is not clear if expression of the polynucleotide of the present Invention is correlated with a specific change in physiology, for example, or with a disease state. Since this asserted utility is also not present in mature form, so that it could be readily used in a real world sense, the asserted utility is not substantial.

9) *To detect and treat cancer.* Paragraph 513 of the instant Specification sets forth the results of assays to determine the expression of clone DNA66658-1584 in selected tissues:

"Molecule is more highly expressed in: as compared to: DNA66658-1584 normal lung /lung [t]umor; melanoma tumor /normal skin"

However, a slight increase or decrease in clone copies in tumors is not indicative of a specific or substantial utility for PRO1328 for use as an agent to detect or treat cancer. An increase in copy numbers of nucleic acids encoding PRO1328 in a cancerous tissue is more likely due to an increased number of chromosomes, a very common characteristic of cancerous and non-cancerous epithelial cells (see, for example: Hittelman, W., 2001, Ann. NY. Acad. Sci., 952: 1-12, especially pages 8 and 9, and; Crowell, et al, 1996, Cancer Epidemiol. 5: 631-637), not because PRO1328 is a target for therapeutic intervention in certain cancers. The asserted utility is therefore not substantial. Experiments confirming the specificity and substantial utility



Art Unit: 1647

of PRO1328 in terms of mRNA concentration and protein expression were not performed.

Significant further experimentation would be required of the skilled artisan to determine whether PRO1328 is expressed in certain cancers to the extent that antagonists (e.g., antibodies) directed against the protein encoded by DNA66658-1584 (PRO1328) would be expected to have utility in cancer therapy. Thus, the asserted utility is not substantial.

Claims 1-20 are also rejected under 35 U.S.C. 112, first paragraph. Specifically, since the claimed invention is not supported by either a specific and substantial asserted utility or a well established utility for the reasons set forth above, one skilled in the art clearly would not know how to use the claimed invention.

Applicants have implied that the PRO1328 polypeptide is a secreted protein that can be used to diagnose or treat cancer. Examples from the secreted polypeptide art demonstrate, in some cases, polypeptides with high homology having a wide-variety of functions in organisms (see Hesselgesser, et al, 1997, Methods in Enzymology, 287: 59-69, see pages 59 and 64-66) and in other cases, many different possible structures for secreted proteins that are considered related as to function (Blease, et al, 2000, Resp. Res., 1(1): 54-61). However, Applicants have not associated the disclosed PRO1328 polypeptide with any type or genus of secreted peptide.

Furthermore, the results of the experimental assays are not considered substantial because it is known in the art that increased mRNA levels do not necessarily correlate to an increase in protein production, or do not correlate well. For instance, Haynes et al. (Electrophoresis, 1998, 19: 1862-1871) studied 80 proteins relatively homogenous in half-life and expression level, and found no strong correlation between protein and transcript levels for many genes. Equivalent

Art Unit: 1647

RNA levels translated into changes in protein concentrations which varied by more than 50 fold.

Haynes et al concluded that the protein levels cannot be accurately predicted from the levels of the corresponding mRNA transcripts (see page 1863, the second paragraph of the left column, and Figure 1). Further, even if the increased PRO1328 mRNA correlates to an increase in protein production, it is still unclear the biological significance of PRO1328 in cancer cell proliferation (paragraph 531). The specification fails to provide evidence to illustrate the relationship between PRO1328 polypeptide and a positive change cancer cell proliferation, which would support the assertion that PRO1328 may be useful for therapeutic treatment. As many proteins may regulate the PRO1328 peptide, one cannot extrapolate from increased mRNA levels that any protein, such as PRO1328, would be a useful target for treating cancer. Furthermore, of the two measurements taken, only one showed an increase in PRO1328 expression in tumor cells.

Due to the large quantity of experimentation necessary to determine an activity or property of the disclosed polypeptide such that it can be determined how to use the claimed polynucleotides encoding SEQ ID NO: 94 and to screen for activity, the lack of direction/guidance presented in the specification regarding same, the absence of working examples directed to same, the complex nature of the invention, the state of the prior art establishing that biological activity cannot be predicted based on structural similarity, the unpredictability of the effects of mutation on protein structure and function, and the breadth of the claims which fail to recite particular biological activities, undue experimentation would be required of the skilled artisan to make and/or use the claimed invention in its full scope.

***35 USC § 112, first paragraph – Written Description.***

Claims 1-6 and 8-20 are also rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor, at the time the application was filed, had possession of the claimed invention.

The claims are directed to nucleotide(s) which encode a polypeptide of 257 amino acids (see Figure 93). Further claim limitations are presented to isolated nucleic acids having at least 80-99% sequence identity to a nucleic acid encoding the polypeptide of SEQ ID NO: 94, or the polypeptide of SEQ ID NO: 94 lacking its associated signal peptide. Claims are also presented to nucleic acids encoding the extracellular domain of the protein.

The specification teaches a polynucleotide (SEQ ID NO: 93) and a polypeptide (SEQ ID NO: 94). However, the specification does not teach functional or structural characteristics of all claimed polynucleotides. The description of one polynucleotide encoding a PRO polypeptide (SEQ ID NO: 94) is not adequate written description of an entire genus of functionally equivalent polynucleotides and polypeptides.

To provide evidence of enablement of a claimed genus, the specification must provide sufficient distinguishing identifying characteristics of the genus. The factors to be considered include disclosure of complete or partial structure, physical and/or chemical properties,

Art Unit: 1647

functional characteristics, structure/function correlation, methods of making the claimed product, or any combination thereof. In this case, the only factor present in the claim is a partial structure in the form of a recitation of percent identity or protein domains that have not been adequately identified. There is not even identification of any particular portion of the structure that must be conserved. Accordingly, in the absence of sufficient recitation of distinguishing identifying characteristics, the specification does not provide adequate written description of the claimed genus.

*Vas-Cath Inc. v. Mahurkar*, 19USPQ2d 1111, clearly states that “applicant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession *of the invention*. The invention is, for purposes of the ‘written description’ inquiry, *whatever is now claimed*” (See page 1117). The specification does not “clearly allow persons of ordinary skill in the art to recognize that [he or she] invented what is claimed” (See *Vas-Cath* at page 1116).

With the exception of the sequences referred to above, the skilled artisan cannot envision the detailed chemical structure of all claimed polynucleotides and all encompassed PRO polypeptides, and therefore, would not know how to use them. Conception is not achieved until reduction to practice has occurred, regardless of the complexity or simplicity of the method of use. Adequate written description requires more than a mere statement that it is part of the invention and reference to a potential method of use. The nucleotide itself is required. See *Fiers v. Revel*, 25 USPQ2d 1601 at 1606 (CAFC 1993) and *Amgen Inc. v. Chugai Pharmaceutical Co. Ltd.*, 18 USPQ2d 1016.

Art Unit: 1647

One cannot describe what one has not conceived. See *Fiddes v. Baird*, 30 USPQ2d 1481 at 1483. In *Fiddes*, claims directed to mammalian FGF's were found to be unpatentable due to lack of written description for that broad class. The specification provided only the bovine sequence.

Therefore, only an isolated nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO: 93 and a polypeptide comprising the amino acid sequence of SEQ ID NO: 94, but not the full breadth of the claims, meets the written description provision of 35 U.S.C. §112, first paragraph. Applicant is reminded that *Vas-Cath* makes clear that the written description provision of 35 U.S.C. §112 is severable from its enablement provision (see page 1115).

***35 USC § 112, first paragraph – Deposit Rules***

Claims 1-6, 8-10 and 11-13 are also rejected under 35 U.S.C. § 112, first paragraph, as not complying with the enablement requirement. The invention appears to employ novel nucleic acid molecules (i.e., clone: DNA66658-1328). Since the nucleic acid molecules are essential to the claimed invention they must be obtainable by a repeatable method set forth in the specification or otherwise readily available to the public. If the nucleic acid molecules are not so obtainable or available, the requirements of 35 U.S.C. § 112 may be satisfied by a deposit of the nucleic acid molecules. The Specification at paragraph 442 indicates that the deposit was made under the Budapest treaty. However, Applicants have failed to provide a copy of the deposit receipt. If a deposit is made under the Budapest Treaty, then an affidavit or declaration by Applicant, or a statement by an attorney of record over his or her signature and registration number, stating that the specific nucleic acid molecules have been deposited under the Budapest

Art Unit: 1647

Treaty and that the nucleic acid molecules will be irrevocably and without restriction or condition released to the public upon the issuance of a patent, would satisfy the deposit requirement made herein. If a deposit is not made under the Budapest Treaty, then in order to certify that the deposit meets the criteria set forth in 37 C.F.R. §§ 1.801-1.809, Applicant may provide assurance of compliance by an affidavit or declaration, or by a statement by an attorney of record over his or her signature and registration number, showing that

(a) during the pendency of this application, access to the invention will be afforded to the Commissioner upon request;

(b) all restrictions upon availability to the public will be irrevocably removed upon granting of the patent;

(c) the deposit will be maintained in a public depository for a period of 30 years or 5 years after the last request or for the effective life of the patent, whichever is longer;

(d) a test of the viability of the biological material at the time of deposit will be made (see 37 C.F.R. § 1.807); and

(e) the deposit will be replaced if it should ever become inviable. Applicant's attention is directed to M.P.E.P. §2400 in general, and specifically to §2411.05, as well as to 37 C.F.R. § 1.809(d), wherein it is set forth that "the specification shall contain the accession number for the deposit, the date of the deposit, the name and address of the depository, and a description of the deposited material sufficient to specifically identify it and to permit examination.

***Claim Rejections - 35 USC § 112, second paragraph***

The following is a quotation of the second paragraph of 35 U.S.C. 112:

**The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.**

Claims 1-6, 9, 10 and 14 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claims 1-6, 9, 10 and 14 are rendered indefinite because of the phrase “extracellular domain.” The metes and bounds of Claims 1-6, 9, 10 and 14 are indefinite in view of the instant Specification which implies and states that the polypeptide encoded by the claimed polynucleotide(s) is a secreted protein. Such an “extracellular domain” would be found in a cleaved transmembrane protein, for example, along with an intracellular domain, but is not recognized in secreted proteins since they are entirely “extracellular.”

Claim 15 is rendered indefinite because of the phrase “stringent conditions,” which is a conditional term. In other words, for example, some nucleic acids which are able to hybridize under stringent conditions would be unable to hybridize under non-stringent conditions. The metes and bounds of the claim, therefore, cannot be ascertained. This rejection can be overcome by supplying specific conditions, supported by the specification, which the Applicants consider “stringent,” or by removing the indefinite phrase.

Art Unit: 1647

***Claim Rejections- 35 USC § 102***

The following are quotations of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

**(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.**

Claim 16 is rejected under 35 U.S.C. 102(b) as being unpatentable over Laird, G. (2001, Accession No. AL445222). Laird, G. discloses a polynucleotide sequence which contains several lengths of nucleotides 10 or more bases long which are identical to 10-base segments of the PRO1328 polynucleotide in the instant application (for example, residues 427-447). This reference meets the limitations of Claim 16 of polynucleotides "at least 10 nucleotides in length."

**References used for a better understanding of the art, but not cited in this Office Action:**

Marlow, et al, 2003, Biochem. Biophys. Res. Comm., 305: 502-509.

Clark, et al, 2003, Genome Res., 13: 2265-2270.

**Conclusion:** Claims 1-20 are rejected for the reasons recited above.

**Advisory information**

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sandra Wegert whose telephone number is (571) 272-0895. The examiner can normally be reached Monday - Friday from 9:00 AM to 5:00 PM (Eastern Time). If attempts to reach the examiner by telephone are unsuccessful, the Examiner's supervisor, Brenda Brumback, can be reached at (571) 272-0961.



Art Unit: 1647

The fax number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

SLW

7/26/04



ELIZABETH KEMMERER  
PRIMARY EXAMINER